Chromosome Disorders: Clinical Trials

962 trials for Chromosome Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

545 completed, 143 recruiting, 107 unknown, 65 terminated. 324 Not applicable, 162 Phase 2, 85 Phase 3, 58 Phase 1, 36 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable324Completed 197, Recruiting 53, Unknown 34, Not yet recruiting 12, Terminated 12, Active not recruiting 11, Enrolling by invitation 4, Withdrawn 1
Phase 2162Completed 96, Recruiting 18, Terminated 12, Active not recruiting 9, Not yet recruiting 9, Withdrawn 9, Unknown 7, Suspended 2
Phase 385Completed 39, Terminated 18, Recruiting 12, Active not recruiting 8, Unknown 4, Withdrawn 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 158Completed 42, Terminated 4, Recruiting 3, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 2, Enrolling by invitation 1
Phase 436Completed 24, Recruiting 7, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1
Early Phase 12Completed 2

Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome
S247240 Low dose, S247240 Middle dose, S247240 High dose - Fragile X Syndrome (FXS)
Phase 2Not yet recruitingInstitut de Recherches Internationales Servier (I.R.I.S.)1002027-01-252026-11-12
Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation
Regulating Together group therapy - Prader-Willi Syndrome
Not applicableRecruitingChildren's Mercy Hospital Kansas City102027-01-012026-09-02
Creating Mobility-supported Home Play Environments to Enhance Development in Infants With Down Syndrome
PUMA - Down Syndrome
Not applicableNot yet recruitingBoston University Charles River Campus602027-01-012026-11-13
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
Executive Function Play Opportunities for Children With Down Syndrome
EXPO, EXPO Extended, EXPO Foundations - Down Syndrome, Trisomy 21
Not applicableNot yet recruitingColorado State University1502026-12-012026-10-30
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-12-012026-10-30
Effects of a Pacifier on Obstructive Sleep Apnea and Its Repercussions in Infants With Down Syndrome
CURAPROX pacifier use, Pacifier diary, Polysomnography (PSG) to explore OSA - Obstructive Sleep Apnea, Down Syndrome (Trisomy 21)
Not applicableNot yet recruitingHospices Civils de Lyon502026-11-022026-10-07
Hematological Profile in Children With Numerical Chromosomal Disorders
Down Syndrome, Turner Syndrome
Not yet recruitingAssiut University1582026-11-022026-10-29
Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome
N-acetyl cysteine, Placebo - Cornelia de Lange Syndrome
Phase 2Not yet recruitingJohns Hopkins University102026-11-012026-08-14
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
EMPOWER-ND - Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD)
Not applicableNot yet recruitingBoston University Charles River Campus502026-11-012026-10-27
Escalating Doses of Memantine in Down Syndrome (MEDS-123)
Memantine - Down Syndrome, Intellectual Disability
Phase 1Not yet recruitingUniversity Hospitals Cleveland Medical Center252026-10-142026-10-05
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial
Not yet recruitingAssistance Publique - Hôpitaux de Paris14162026-10-012026-09-02
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
Ublituximab - Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21)
Phase 2Not yet recruitingJonathan Santoro202026-10-012026-09-23
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
obudanersen - Angelman Syndrome
Phase 3RecruitingIonis Pharmaceuticals, Inc.302026-09-302026-10-20
A Natural History Study of Angelman Syndrome
Angelman Syndrome, Neurodevelopmental Conditions
RecruitingMassachusetts General Hospital402026-09-092026-10-13
Vestibular Stimulation Versus Foot Intrinsic Muscle Exercises in Children With Down Syndrome
Vestibular Stimulation Exercises, Foot Intrinsic Muscle Exercises - Down Syndrome, Balance Impairment
Not applicableNot yet recruitingShalamar Institute of Health Sciences482026-09-022026-08-21
Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome
Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch - Turner Syndrome, Primary Ovarian Insufficiency
Phase 2Not yet recruitingChildren's National Research Institute152026-09-012026-08-25
Home and Community Use of a Suspension Walker in Pre-Walking Infants With Down Syndrome
suspension walker - Down Syndrome
Not applicableNot yet recruitingUniversity of Southern California122026-09-012026-06-05
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
MIB-626, Placebo - Down Syndrome (DS)
Phase 1Not yet recruitingBrigham and Women's Hospital242026-08-312026-08-19
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Mivelsiran, Placebo - Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Phase 2RecruitingAlnylam Pharmaceuticals582026-08-172026-10-13

Showing 20 of 962. Sign in to see all of them.

Narrower conditions

Down Syndrome (434)  ·  Prader-Willi Syndrome (140)  ·  Turner Syndrome (124)  ·  Fragile X Syndrome (115)  ·  Angelman Syndrome (51)  ·  Klinefelter Syndrome (47)  ·  DiGeorge Syndrome (46)  ·  Autism Spectrum Disorder (37)  ·  Intellectual Disability (37)  ·  Obesity (37)  ·  Alzheimer Disease (31)  ·  Genetic Diseases, Inborn (31)  ·  Williams Syndrome (29)  ·  Sleep Apnea, Obstructive (27)  ·  Trisomy 18 Syndrome (27)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (959)  ·  Congenital Abnormalities (948)  ·  Genetic Diseases, Inborn (931)  ·  Nervous System Diseases (778)  ·  Neurologic Manifestations (714)  ·  Neurobehavioral Manifestations (706)  ·  Abnormalities, Multiple (697)  ·  Intellectual Disability (675)  ·  Sex Chromosome Disorders (266)  ·  Endocrine System Diseases (224)  ·  Cardiovascular Diseases (216)  ·  Heart Diseases (216)  ·  Pathological Conditions, Signs and Symptoms (207)  ·  Cardiovascular Abnormalities (194)

Interventions

Human Growth Hormone (30)  ·  Blood Specimen Collection (15)  ·  Growth Hormone (15)  ·  Oxytocin (12)  ·  Estradiol (8)  ·  Exercise (7)  ·  Cytarabine (6)  ·  Donepezil (6)  ·  Metformin (6)  ·  Minocycline (6)  ·  Surveys and Questionnaires (6)  ·  gaboxadol (6)  ·  mavoglurant (6)  ·  Leucovorin (5)  ·  Memantine (5)

Sponsors

Riphah International University (48)  ·  University of Colorado, Denver (23)  ·  Assistance Publique - Hôpitaux de Paris (18)  ·  University Hospital, Toulouse (17)  ·  University of Aarhus (17)  ·  Children's Hospital Medical Center, Cincinnati (16)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (15)  ·  Novo Nordisk A/S (14)  ·  Hoffmann-La Roche (13)  ·  Cairo University (12)  ·  Hospices Civils de Lyon (10)  ·  Institut Jerome Lejeune (10)  ·  Massachusetts General Hospital (10)  ·  National Human Genome Research Institute (NHGRI) (9)  ·  Seaside Therapeutics, Inc. (9)

Countries

United States (473)  ·  France (129)  ·  Spain (78)  ·  Canada (59)  ·  Italy (53)  ·  Pakistan (50)  ·  United Kingdom (46)  ·  Denmark (36)  ·  Australia (33)  ·  Netherlands (26)  ·  Germany (25)  ·  Egypt (23)  ·  Turkey (Türkiye) (23)  ·  Belgium (21)  ·  Israel (19)

Top investigators

Elizabeth Berry-Kravis, MD, PhD (5)  ·  M. Louise Markert, MD, PhD (5)  ·  Wen-Hann Tan, BMBS (5)  ·  Joaquin Espinosa, PhD (4)  ·  Randi J Hagerman, MD (4)  ·  Allan L Reiss (3)  ·  Bryan King, MD, PhD (3)  ·  Carlos A. Bacino, MD (3)  ·  Craig Erickson, MD (3)

Results publications

PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 17284531, PMID 36978128, PMID 33395098, PMID 38671361, PMID 15100156, PMID 18155964, PMID 20978268, PMID 22005709, PMID 22281937, PMID 23607606, PMID 25834952, PMID 26764156, PMID 26855682, PMID 29718281, PMID 32542985, PMID 33232306, PMID 35794169, PMID 37919617, PMID 10417280, PMID 10518081, PMID 10586155, PMID 10599727, PMID 10599729, PMID 11531930, PMID 12466334, PMID 12520259, PMID 12629094, PMID 12642839, PMID 12702512, PMID 12820840, PMID 12889762, PMID 15100681, PMID 15784709, PMID 15900109, PMID 16282778, PMID 16509530, PMID 16757526, PMID 16801584, PMID 16814942, PMID 17344250, PMID 17535868, PMID 17875973, PMID 18296460, PMID 18333898, PMID 19104360

NIH funding

K12HD043494 (7), R01AI047040 (7), R01AI054843 (6), U10CA180886 (5), UL1TR001082 (5), 2025 (4), R56AI047040 (4), 2009 (3), 2023 (3), 2017 (2), K23HD109375 (2), R01AG016381 (2), R01HD071981 (2), R61HL151253 (2), U10CA098543 (2)